Bacterial infection Dx firm raises €18.5m
This article was originally published in Clinica
A consortium of European venture capital firms have invested €18.5m ($27.1m) of series A financing in German molecular diagnostics start-up Curetis. The Holzgerlingen-based company will use the proceeds to complete development of its first range of products and gain the necessary regulatory approvals to commercialise them. The initial products will focus on diagnosing severe bacterial infections, such as pneumonia. Investors in Curetis include Life Sciences Partners; BioMedPartners; ERP-Startfonds of the KfW Bankengruppe; and aeris CAPITAL, which also provided the company with seed funding.